PARP1 and neoplasm: A combination with established (platinum-based) chemotherapy, clinically applied adjuvant therapies (PARP and angiogenic inhibitors) or novel targeted therapies (a.o. chimergic antigen receptor T-cells, nanoparticles, immunotherapy, tyrosine kinase inhibitors, oncolytic viruses) could be fruitful for TRT as synergistic effects may lower the required administered activity for tumor control as well as radiation-induced toxicity to healthy tissues 156.